Cargando…
Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients
Cross-linking of α2-plasmin inhibitor (α2-PI) to fibrin by activated factor XIII (FXIIIa) is essential for the inhibition of fibrinolysis. Little is known about the factors modifying α2-PI incorporation into the fibrin clot and whether the extent of incorporation has clinical consequences. Herein we...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996613/ https://www.ncbi.nlm.nih.gov/pubmed/33669007 http://dx.doi.org/10.3390/biom11030347 |
_version_ | 1783670143627296768 |
---|---|
author | Bagoly, Zsuzsa Baráth, Barbara Orbán-Kálmándi, Rita Szegedi, István Bogáti, Réka Sarkady, Ferenc Csiba, László Katona, Éva |
author_facet | Bagoly, Zsuzsa Baráth, Barbara Orbán-Kálmándi, Rita Szegedi, István Bogáti, Réka Sarkady, Ferenc Csiba, László Katona, Éva |
author_sort | Bagoly, Zsuzsa |
collection | PubMed |
description | Cross-linking of α2-plasmin inhibitor (α2-PI) to fibrin by activated factor XIII (FXIIIa) is essential for the inhibition of fibrinolysis. Little is known about the factors modifying α2-PI incorporation into the fibrin clot and whether the extent of incorporation has clinical consequences. Herein we calculated the extent of α2-PI incorporation by measuring α2-PI antigen levels from plasma and serum obtained after clotting the plasma by thrombin and Ca(2+). The modifying effect of FXIII was studied by spiking of FXIII-A-deficient plasma with purified plasma FXIII. Fibrinogen, FXIII, α2-PI incorporation, in vitro clot-lysis, soluble fibroblast activation protein and α2-PI p.Arg6Trp polymorphism were measured from samples of 57 acute ischemic stroke patients obtained before thrombolysis and of 26 healthy controls. Increasing FXIII levels even at levels above the upper limit of normal increased α2-PI incorporation into the fibrin clot. α2-PI incorporation of controls and patients with good outcomes did not differ significantly (49.4 ± 4.6% vs. 47.4 ± 6.7%, p = 1.000), however it was significantly lower in patients suffering post-lysis intracranial hemorrhage (37.3 ± 14.0%, p = 0.004). In conclusion, increased FXIII levels resulted in elevated incorporation of α2-PI into fibrin clots. In stroke patients undergoing intravenous thrombolysis treatment, α2-PI incorporation shows an association with the outcome of therapy, particularly with thrombolysis-associated intracranial hemorrhage. |
format | Online Article Text |
id | pubmed-7996613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79966132021-03-27 Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients Bagoly, Zsuzsa Baráth, Barbara Orbán-Kálmándi, Rita Szegedi, István Bogáti, Réka Sarkady, Ferenc Csiba, László Katona, Éva Biomolecules Article Cross-linking of α2-plasmin inhibitor (α2-PI) to fibrin by activated factor XIII (FXIIIa) is essential for the inhibition of fibrinolysis. Little is known about the factors modifying α2-PI incorporation into the fibrin clot and whether the extent of incorporation has clinical consequences. Herein we calculated the extent of α2-PI incorporation by measuring α2-PI antigen levels from plasma and serum obtained after clotting the plasma by thrombin and Ca(2+). The modifying effect of FXIII was studied by spiking of FXIII-A-deficient plasma with purified plasma FXIII. Fibrinogen, FXIII, α2-PI incorporation, in vitro clot-lysis, soluble fibroblast activation protein and α2-PI p.Arg6Trp polymorphism were measured from samples of 57 acute ischemic stroke patients obtained before thrombolysis and of 26 healthy controls. Increasing FXIII levels even at levels above the upper limit of normal increased α2-PI incorporation into the fibrin clot. α2-PI incorporation of controls and patients with good outcomes did not differ significantly (49.4 ± 4.6% vs. 47.4 ± 6.7%, p = 1.000), however it was significantly lower in patients suffering post-lysis intracranial hemorrhage (37.3 ± 14.0%, p = 0.004). In conclusion, increased FXIII levels resulted in elevated incorporation of α2-PI into fibrin clots. In stroke patients undergoing intravenous thrombolysis treatment, α2-PI incorporation shows an association with the outcome of therapy, particularly with thrombolysis-associated intracranial hemorrhage. MDPI 2021-02-25 /pmc/articles/PMC7996613/ /pubmed/33669007 http://dx.doi.org/10.3390/biom11030347 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Bagoly, Zsuzsa Baráth, Barbara Orbán-Kálmándi, Rita Szegedi, István Bogáti, Réka Sarkady, Ferenc Csiba, László Katona, Éva Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title | Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title_full | Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title_fullStr | Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title_full_unstemmed | Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title_short | Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients |
title_sort | incorporation of α2-plasmin inhibitor into fibrin clots and its association with the clinical outcome of acute ischemic stroke patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996613/ https://www.ncbi.nlm.nih.gov/pubmed/33669007 http://dx.doi.org/10.3390/biom11030347 |
work_keys_str_mv | AT bagolyzsuzsa incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT barathbarbara incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT orbankalmandirita incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT szegediistvan incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT bogatireka incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT sarkadyferenc incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT csibalaszlo incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients AT katonaeva incorporationofa2plasmininhibitorintofibrinclotsanditsassociationwiththeclinicaloutcomeofacuteischemicstrokepatients |